New combo therapy aims to improve survival in advanced nose cancer

NCT ID NCT07459296

Recruiting now Disease control Sponsor: First Affiliated Hospital of Guangxi Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether a new drug (Becotatug vedotin) plus immunotherapy (sintilimab) and standard chemoradiation works better than current standard treatment for high-risk nasopharyngeal cancer. About 266 adults with advanced but non-spread cancer will be randomly assigned to one of two treatment groups. The main goal is to see if the new combination improves 3-year survival without cancer returning.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA (NPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASOPHARYNGEAL CARCINOMA (NPC)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The First Affiliated Hospital of Guangxi Medical University
RECRUITING

Nanning, Guangxi, 530021, China

Contact Phone: •••-•••-•••• Email: •••••@•••••